Drug Advancement: Social media chatter centers on Sunshine Biopharma's progress with its lead coronavirus drug candidate, now entering IND-enabling studies with demonstrated nanomolar potency against multiple SARS-CoV-2 variants. Analysts on the platform note the drug's strong oral bioavailability and lung enrichment across species as key positives from recent in-vivo data. Discussions emphasize the dose-dependent suppression of pulmonary viral replication observed in tests.
Investor Sentiment: Participants describe the broad-spectrum activity as a notable step forward for the company's pipeline, sparking questions about next development milestones. Some observers highlight the Fort Lauderdale-based firm's focus on these studies as potentially impactful for future applications. Overall, the tone remains measured yet engaged with the scientific details shared.
Note: This discussion summary was generated from an AI condensation of post data.
Sunshine Biopharma Insider Trading Activity
Sunshine Biopharma insiders have traded $SUNB stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $SUNB stock by insiders over the last 6 months:
- JOHN WASHBURN (Chief Operating Officer) has made 0 purchases and 2 sales selling 6,702 shares for an estimated $477,517.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Sunshine Biopharma Hedge Fund Activity
We have seen 325 institutional investors add shares of Sunshine Biopharma stock to their portfolio, and 171 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 14,680,354 shares (+3092.5%) to their portfolio in Q2 2026, for an estimated $1,098,237,282
- ABRAMS BISON INVESTMENTS, LLC removed 10,502,327 shares (-83.6%) from their portfolio in Q2 2026, for an estimated $785,679,082
- ROTHSCHILD & CO WEALTH MANAGEMENT UK LTD added 8,653,829 shares (+inf%) to their portfolio in Q2 2026, for an estimated $647,392,947
- NORGES BANK added 7,273,452 shares (+inf%) to their portfolio in Q2 2026, for an estimated $544,126,944
- GEODE CAPITAL MANAGEMENT, LLC added 6,813,505 shares (+1698.3%) to their portfolio in Q2 2026, for an estimated $509,718,309
- STATE STREET CORP added 5,891,214 shares (+159222.0%) to their portfolio in Q2 2026, for an estimated $440,721,719
- AMUNDI added 4,214,807 shares (+inf%) to their portfolio in Q1 2026, for an estimated $274,341,787
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Sunshine Biopharma Price Targets
Multiple analysts have issued price targets for $SUNB recently. We have seen 5 analysts offer price targets for $SUNB in the last 6 months, with a median target of $86.0.
Here are some recent targets:
- Tami Zakaria from JP Morgan set a target price of $74.0 on 06/24/2026
- Kyle Menges from Citigroup set a target price of $90.0 on 06/24/2026
- James Rose from Barclays set a target price of $90.0 on 06/22/2026
- Karl Green from RBC Capital set a target price of $80.0 on 06/22/2026
- Will Kirkness from Bernstein set a target price of $86.0 on 05/12/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
